How effective are intravenous immunoglobulins in pediatric dermatology?

References

• Ammann AJ, Ashman RF, Buckley RH et al. Use of intravenous gammaglobulin in antibody immunodeficiency: results of multicenter controlled trials. Clin. Immunol. Immunopathol.22, 60–67 (1982).
   PubMedGoogle Scholar
• Imbach P, Barandun S, d’ Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet36, 1228–1231 (1982).
   Google Scholar
• Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet342, 678 (1993).
   PubMed Web of Science ®Google Scholar
• Blasczyk R, Westhoff V, Gross-Wilde H. Soluble CD4, CD8 and HLA molecules in commercial immunoglobulin preparations. Lancet341, 789–790 (1993).
   PubMed Web of Science ®Google Scholar
• Siegel J. The product. All intravenous immunoglobulins are not equivalent. Pharmacotherapy25(11 Pt 2), S78–S84 (2005).
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Differences between IGIV products. Int. Immunopharmacol.6, 592–599 (2006).
   PubMed Web of Science ®Google Scholar
• Schiff RI. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity. Rev. Infect. Dis.8(Suppl. 4), S449–S456 (1986).
   Google Scholar
• Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy26, 813–827 (2006).
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med.345, 747–755 (2001).
   PubMed Web of Science ®Google Scholar
• Sewell WAC, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology107, 387–393 (2002).
   PubMed Web of Science ®Google Scholar
• Misra N, Bayary J, Dasgupta S et al. Intravenous immunoglobulin and dendritic cells. Clin. Rev. Allergy Immunol.29, 201–205 (2005).
   PubMed Web of Science ®Google Scholar
• Lacroix-Desmazes S, Kaveri SV, Mouthon L et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Methods216, 117–137 (1998).
   PubMed Web of Science ®Google Scholar
• Katz U, Achiron, A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun. Rev.6, 257–259 (2007).
   PubMed Web of Science ®Google Scholar
• Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulins. Transfus. Med. Rev.17, 241–251 (2003).
   PubMed Web of Science ®Google Scholar
• Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side effects. Eur. Neurol.50, 172–175 (2003).
   PubMed Web of Science ®Google Scholar
• Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int. Immunopharmacol.6, 535–542 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch. Dermatol.139, 1051–1059 (2003).
   PubMedGoogle Scholar
• Katz KA, Hivnor CM, Geist DE et al. Stroke and deep vein thrombosis complicating intravenous immunoglobulin infusions. Arch. Dermatol.139, 991–993 (2003).
   PubMed Web of Science ®Google Scholar
• Mushtaq T, Ahmed SF. The impact of corticosteroids on growth and bone. Arch. Dis. Child.87, 93–96 (2002).
   PubMed Web of Science ®Google Scholar
• Schubert S, Renner C, Hammer M et al. Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J. Heart Lung Transplant.27, 100–105 (2008).
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulins: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol.117, S525–S553 (2006).
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Routes JM. Immunodeficiency overview. Prim. Care35, 159–173 (2008).
   PubMed Web of Science ®Google Scholar
• Buckley RH, Schiff RI. The use of intravenous immunoglobulin in immunodeficiency diseases. N. Engl. J. Med.325, 110–117 (1991).
   PubMed Web of Science ®Google Scholar
• Quartier P, Debre M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr.134, 589–596 (1993).
   Google Scholar
• Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy Clin. Immunol.109, 1001–1004 (2002).
   PubMed Web of Science ®Google Scholar
• Simon HV, Spath PJ. IVIG: mechanism of action. Allergy58, 543–552 (2003).
   PubMed Web of Science ®Google Scholar
• Mouthon L, Lortholary O. Intravenous immunoglobulins in infectious diseases: where do we stand? Clin. Microbiol. Infect.9, 333–338 (2003).
   PubMed Web of Science ®Google Scholar
• Kim DS. Kawasaki disease. Yonsei Med. J.47, 759–772 (2006).
   PubMed Web of Science ®Google Scholar
• Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N. Engl. J. Med.315, 341–347 (1986).
   PubMed Web of Science ®Google Scholar
• Morikawa Y, Ohashi Y, Harada K et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr. Jpn36, 347–354 (1994).
   PubMedGoogle Scholar
• Xu C, Poirier B, Van Huyen JP et al. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases. Am. J. Pathol.153, 1257–1266 (1998).
   PubMed Web of Science ®Google Scholar
• Tremoulet AH, Best BM, Song S et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J. Pediatr.153, 117–121 (2008).
   PubMed Web of Science ®Google Scholar
• Blanchette U, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr. Clin. North Am.55, 393–420 (2008).
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB. Idiopathic thrombocytopenic purpura. Arch. Dis. Child.83, 220–222 (2000).
   PubMed Web of Science ®Google Scholar
• George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practical guideline developed by explicit methods for American Society of Hematology. Blood88, 3–40 (1996).
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Idiopathic thrombocytopenis purpura: an old disease revisited in the era of evidence based medicine Hematologica88, 1081–1087 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Kopecky KG, Jocom J et al. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulins in bone marrow transplantation. N. Engl. J. Med.323, 705–709 (1990).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Antin JH, Wolff SL et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogenic bone marrow transplant. Bone Marrow Transplant.28, 187–196 (2001).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Chevret S, Legrand M et al. IV immune globulin prophylaxis in allogenic sibling stem cell transplant patients: a randomized, dose effect, placebo-controlled, double-blind, multicenter trial. Blood98, 779a (2001) (Abstract 3242).
   Google Scholar
• Viard I, Wehril P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulins. Science282, 490–493 (1998).
   PubMed Web of Science ®Google Scholar
• Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch. Dermatol.139, 26–32 (2003).
   PubMed Web of Science ®Google Scholar
• Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch. Dermatol.139, 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm. Venereol.83, 430–432 (2003).
   PubMed Web of Science ®Google Scholar
• Bachot N, Revuz J, Roujeauv JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective non comparative study showing no benefit on mortality and progression. Arch. Dermatol.139, 33–36 (2003).
   PubMedGoogle Scholar
• Brown KM, Silver GM, Halrez M, Walazzek P, Sandroni A, Ganelli R. Toxic epidermal necrolysis: does immunoglobulin make a difference? J. Burn Care Rehabil.25, 81–88 (2004).
   PubMedGoogle Scholar
• Schneck J, Fagot J, Sckuta P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatment on the mortality of Stevens Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J. Am. Acad. Dermatol.58, 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Morici MV, Galen WK, Shetty AK et al. Intravenous immunoglobulin therapy for children with Stevens Johnson Syndrome. J. Rheumatol.22, 231–233 (2000).
   Google Scholar
• Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J. Am. Acad. Dermatol.47, 548–552 (2002).
   PubMed Web of Science ®Google Scholar
• Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens–Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics112(6 Pt 1), 1430–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulin in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J. Dermatol. Venereol. Leprol.71, 398–400 (2005).
   PubMedGoogle Scholar
• Scheurman O, Nofech-Moses Y, Rachmel A, Ashkenazi S. Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immunoglobulin. Pediatrics107, E14 (2001).
   PubMed Web of Science ®Google Scholar
• Arca E, Köse O, Erbil AH, Nisanci M, Akar A, Gür AR. A 2-year old girl with Stevens Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin. Pediatr. Dermatol.22, 317–320 (2005).
   PubMed Web of Science ®Google Scholar
• Kühn-Côrdova I, Ramirez-Bouchan D, Gamboa-Mariufo JD. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens Johnson syndrome. Ann. Pediatr. (Barc.)67, 68–73 (2007).
   PubMedGoogle Scholar
• Santos RP, Ramilo O, Barton T. Nevirapine-associated symptoms in a child with human immunodeficiency virus infection. Pediatr. Infec. Dis. J.26, 1053–1056 (2007).
   PubMed Web of Science ®Google Scholar
• Jolles S. A review of high-dose intravenous immunoglobulin (hd IVIg) in the treatment of the autoimmune blistering disorders. Clin. Exp. Dermatol.26, 127–131 (2001).
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Expert Opin. Investig. Drugs13, 1019–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Mydlarski PR, Ho V, Shear NH. Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. J. Cutan. Med. Surg.10, 205–221 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int. Immunopharmacol.6, 557–578 (2006).
   PubMed Web of Science ®Google Scholar
• Daoud YJ, Amin KG. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases. Int. Immunopharmacol.6, 600–606 (2006).
   PubMed Web of Science ®Google Scholar
• Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br. J. Dermatol.140, 865–874 (1999).
   PubMed Web of Science ®Google Scholar
• Wetter DA, Davis MD, Yiannias JA et al. Effectiveness of intravenous immunoglobulin therapy for skin diseases other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin. Proc.80, 41–47 (2005).
   PubMed Web of Science ®Google Scholar
• Segura S, Iranzo P, Martínez-de Pablo I et al. High-dose intravenous immunoglobulins for the treatment of autoimmune blistering diseases: evaluation of its use in 19 cases. J. Am. Acad. Dermatol.56, 960–967 (2007).
   PubMed Web of Science ®Google Scholar
• Szép Z, Danilla T, Buchvald D. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins. Cas. Lek. Cesk.144, 700–703 (2005).
   PubMedGoogle Scholar
• Nanda A, Nanda M, Dvorak R, Sl-Sabah H, Alsaleh QA. Bullous pemphigoid (BP) in an infant complicated by tuberculous meningoencephalitis. Int. J. Dermatol.46, 964–966 (2007).
   PubMed Web of Science ®Google Scholar
• Xiao T, Wang YK, He CD, Chen HD. Childhood bullous pemphigoid treated by i.v. immunoglobulin. J. Dermatol.34, 650–653 (2007).
   PubMed Web of Science ®Google Scholar
• Sugawara N, Nagai Y, Matsushima Y, Aoyama K, Ishikawa O. Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy. J. Am. Acad. Dermatol.57, 1084–1089 (2007).
   PubMed Web of Science ®Google Scholar
• Gluth MB, Witman PM, Thompson DM. Upper aerodigestive tract complication in a neonate with linear IgA bullous dermatosis. Int J. Pediatr. Otorhinolaryngol.68, 965–970 (2004).
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol KC, Ahmed AR. Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long term follow-up: influence of treatment on antibody titers to human α6 integrin. Clin. Exp. Immunol.129, 533–540 (2002).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Katz V. IVIG therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity38, 123–137 (2005).
   PubMed Web of Science ®Google Scholar
• Kamali S, Cefle A, Sayarligo M et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol. Int.25, 211–214 (2005).
   PubMed Web of Science ®Google Scholar
• Zadman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin. Rev. Allergy Immunol.29, 219–228 (2005).
   PubMed Web of Science ®Google Scholar
• Nacci F, Righi A, Conforti ML et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann. Rheum. Dis.66, 977–979 (2007).
   PubMed Web of Science ®Google Scholar
• Dalakas MC. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int. Immunopharmacol.6, 550–556 (2006).
   PubMed Web of Science ®Google Scholar
• Sansome A, Dubowitz V. Intravenous immunoglobulins in juvenile dermatomyositis – four year review of nine cases. Arch. Dis. Child.72, 25–28 (1995).
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J. Rheumatol.27, 2498–2503 (2000).
   PubMed Web of Science ®Google Scholar
• Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulins in the treatment of juvenile dermatomyositis adverse reactions are associated with immunoglobulin A content. Pediatrics121, E626–E630 (2008).
   PubMed Web of Science ®Google Scholar
• Chetan G, Mahadevan S, Sulanthung K, Narayanan P. Intravenous immunoglobulin therapy of lupus pneumonitis. Indian J. Pediatr.74, 1032–1033 (2007).
   PubMed Web of Science ®Google Scholar
• Chunharas A, Nuntnarumit P, Hongeng S, Chaunsumrit A. Neonatal lupus erythematosus: clinical manifestations and management. J. Med. Assoc. Thai.85, S1302–S1308 (2002).
   PubMedGoogle Scholar
• Izmirly PM, Rivera TL, Buyon JP. Neonatal lupus syndrome. Rheum. Dis. Clin. North Am.33, 267–285 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon PA. Congenital heart block: clinical features and therapeutic approaches. Lupus16, 642–646 (2007).
   PubMed Web of Science ®Google Scholar
• Wollina U, Looks A, Schneider R, Maak B. Disabling morphea of childhood-beneficial effect of intravenous immunoglobulin therapy. Clin. Exp. Dermatol.23, 292–293 (1998).
   PubMed Web of Science ®Google Scholar
• Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA. Intravenous-administered immunoglobulins as first-choice agent in juvenile dermatomyositis. Ned. Tijdschr. Geneeskd.25, 1979–1982 (1993).
   Google Scholar
• Aslanidis S, Pyrpasopoulou A, Kartali N, Zamboulis C. Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis. Clin. Rheumatol.26, 1198–2000 (2007).
   PubMed Web of Science ®Google Scholar
• Williams L, Chang PY, Park E, Gorson KC, Bayer-Zwirello L. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet. Gynecol.109(2 Pt 2), 561–563 (2007).
   PubMed Web of Science ®Google Scholar
• Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence? Clin. Rev. Allergy Immunol.29, 237–245 (2005).
   PubMed Web of Science ®Google Scholar
• Martinez V, Cohen P, Pagnoux C et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum.58, 308–317 (2008).
   PubMed Web of Science ®Google Scholar
• Finkel TH, Török TJ, Ferguson PJ et al. Chronic parvovirus B19 infection and systemic necrotizing vasculitis: opportunistic infection or aetiological agent? Lancet343, 1255–1258 (1994).
   PubMed Web of Science ®Google Scholar
• Gedalia A, Correa H, Kaiser M, Sorensen R. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am. J. Med. Sci.309, 226–228 (1995).
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Pottier MA, Dupas B. Intravenous immunoglobulin in Henoch–Schönlein purpura. Ann. Int. Med.125, 1013–1014 (1996).
   PubMed Web of Science ®Google Scholar
• Uziel Y, Silverman ED. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin. Exp. Rheumatol.16, 187–189 (1998).
   PubMed Web of Science ®Google Scholar
• González-Femández MA, Garcia-Consuegra J. Polyarteritis nodosa resistant to conventional treatment in pediatric patients. Ann. Pharmacother.41, 885–890 (2007).
   PubMed Web of Science ®Google Scholar
• Fagbemi AA, Torrente F, Hilson AJ, Thomson MA, Heuschkel RB, Murch SH. Massive gastrointestinal haemorrhage in isolate intestinal Henoch–Schonlein purpura with response to intravenous immunoglobulin infusion. Eur J. Pediatr.166, 915–919 (2007).
   PubMed Web of Science ®Google Scholar
• Zaffanello M, Brugnara M, Franchini M. Therapy for children with Henoch–Schonlein purpura nephritis: a systematic review. Scientific World Journal10, 20–30 (2007).
   Google Scholar
• Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch. Dis. Child.70, 335–336 (1994).
   PubMed Web of Science ®Google Scholar
• Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann. Allergy Asthma Immunol.81, 153–158 (1998).
   PubMed Web of Science ®Google Scholar
• Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum level of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1, and Th1 and Th2 cells in severe atopic dermatitis after immunoglobulin therapy. Ann. Allergy Asthma Immunol.84, 345–352 (2000).
   PubMed Web of Science ®Google Scholar
• Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin. Exp. Dermatol.27, 3–7 (2002).
   PubMed Web of Science ®Google Scholar
• Brunetti L, Francavilla R, Miniello VL et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J. Allergy Clin. Immunol.114, 922–927 (2004).
   PubMed Web of Science ®Google Scholar
• O’Donnell BF, Ban RM, Black AK et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br. J. Dermatol.138, 101–106 (1998).
   PubMed Web of Science ®Google Scholar
• Pereira C, Tavares B, Carrapatoso L et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur. Ann. Allergy Clin. Immunol.39, 237–242 (2007).
   PubMedGoogle Scholar
• Jolles S, Hughes J. Use of IVIG in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis and pretibial myxedema. Int. Immunopharmacol.6, 579–591 (2006).
   PubMed Web of Science ®Google Scholar
• Dodig S, Richter D. Chronic autoimmune urticaria in children. Acta Derm. Venereol. Croat.16, 65–71 (2008).
   PubMed Web of Science ®Google Scholar
• Taguchi Y, Takashima S, Yoshida S, Dougu N, Inoue H, Tanaka K. Psoriasis improved by intravenous immunoglobulin therapy. Intern. Med.45, 879–880 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med.355, 1772–1779 (2006).
   PubMed Web of Science ®Google Scholar
• Yo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immunoglobulin for desensitization during renal transplantation. N. Engl. J. Med.359, 242–251 (2008).
   PubMed Web of Science ®Google Scholar